Verve Therapeutics's activity chart (see below) currently has 66 price targets and 53 ratings on display.
Analysts' price targets on this stock were met 10.83% of the time, taking 6.8 days on average.
Our record on Verve Therapeutics covers 12 analysts since 2008. Of the 53 price targets those analysts set on VERV, 4 were reached (8%). The highest performance score on Verve Therapeutics belongs to Eric Joseph of JPMorgan: 9.34, with 1 of 4 targets met in 1 days on average. The latest calls: Kostas Biliouris of BMO cut the target to $13.50 from $20 with a Buy rating on 27 Jun 2025; Mitchell Kapoor of H.C. Wainwright cut the target to $13.50 from $15 with a Buy rating on 18 Jun 2025; Roger Song of Jefferies set a target of $11 with a Buy rating on 18 Jun 2025. Figures as of 18 Nov 2026.
Most recent stock forecast was given by KOSTAS BILIOURIS from OPPENHEIMER on 27-Jun-2025. First documented stock forecast 12-Jul-2021.
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Jun-2022
$13.5
$20
1 years 4 months 26 days ago
(27-Jun-2025)
0/9 (0%)
$2.2 (19.47%)
Buy Since 09-May-2024
$13.5
$15
1 years 5 months 4 days ago
(18-Jun-2025)
0/7 (0%)
$2.38 (21.40%)
Buy Since 13-Apr-2023
$13
$39
1 years 5 months 5 days ago
(17-Jun-2025)
0/10 (0%)
$1.62 (14.24%)
Hold Since 01-Feb-2023
1 years 7 months 1 days ago
(21-Apr-2025)
1/3 (33.33%)
$9 (69.23%)
8
Buy Since 12-Jul-2021
$24
$64
1 years 7 months 7 days ago
(15-Apr-2025)
0/3 (0%)
$19.03 (382.90%)
What is VERV (Verve Therapeutics) average time for price targets to be met?
Which analyst most recently updated their price target on VERV (Verve Therapeutics)?
Which analyst has the most public recommendations on VERV (Verve Therapeutics)?
Which analyst is the currently most bullish on VERV (Verve Therapeutics)?
Which analyst is the currently most reserved on VERV (Verve Therapeutics)?